Myriad Genetics Inc (MYGN) KPIs and segments
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Myriad Genetics's business
Myriad Genetics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Myriad Genetics's fiscal year ends December 31 — Q2 2026 = CQ2 2026 (calendar quarter).
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cancer Care Continuum($M)2 | 114 | 120 | 128 | 116 | |||||||||
United States($M) | 101 | 107 | 113 | 101 | |||||||||
RoW($M) | 13.2 | 13.4 | 14.8 | 14.2 | |||||||||
Hereditary Cancer($M)2 | 93 | 96.3 | 86.3 | 90.5 | 91.5 | 88.1 | 88.9 | 86.5 | |||||
United States($M) | 81.8 | 84.6 | 75.4 | 78.4 | 80.9 | 76.3 | 76.9 | 75.1 | |||||
RoW($M) | 11.2 | 11.7 | 10.9 | 12.1 | 10.6 | 11.8 | 12 | 11.4 | |||||
Prenatal($M)2 | 44.5 | 47.6 | 49.3 | 43.5 | 44.4 | 44.3 | 40 | 39.5 | |||||
United States($M) | 44.5 | 47.5 | 49.2 | 43.4 | 44.2 | 44.1 | 39.8 | 39.4 | |||||
RoW($M) | 0 | 0.10 | 0.10 | 0.10 | 0.20 | 0.20 | 0.20 | 0.10 | |||||
Prenatal Health($M)2 | 39.8 | 41.9 | 47.6 | 49.3 | |||||||||
United States($M) | 39.8 | 41.9 | 47.5 | 49.2 | |||||||||
RoW($M) | 0 | 0 | 0.10 | 0.10 | |||||||||
Pharmacogenomics($M)2 | 38.7 | 37.8 | 31 | 40.6 | 47.7 | 43 | 38.9 | 35.6 | 35.7 | ||||
United States($M) | 38.7 | 37.8 | 31 | 40.6 | 47.7 | 43 | 38.9 | 35.6 | 35.7 | ||||
RoW($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Mental Health($M)2 | 36.8 | 38.3 | 37.8 | 31 | |||||||||
United States($M) | 36.8 | 38.3 | 37.8 | 31 | |||||||||
RoW($M) | 0 | 0 | 0 | 0 | |||||||||
Tumor Profiling($M)2 | 31.5 | 29.5 | 31.4 | 29.3 | 30.7 | 31.6 | 32.6 | 30.9 | 32.1 | 30.2 | |||
United States($M) | 28.8 | 26.7 | 28.3 | 26 | 27.1 | 26.5 | 26.7 | 23.9 | 24 | 22 | |||
RoW($M) | 2.70 | 2.80 | 3.10 | 3.30 | 3.60 | 5.10 | 5.90 | 7 | 8.10 | 8.20 | |||
Earlier reporting (last reported 2024)1 | |||||||||||||
United States($M) | 178 | 187 | 197 | 192 | 198 | 182 | 196 | 196 | 195 | 183 | 176 | 172 | |
RoW($M) | 13.2 | 13.4 | 13.3 | 14 | 14.9 | 14.3 | 15.1 | 17.3 | 16.7 | 19 | 20.3 | 19.7 | |
51 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-07-31.
See a number that looks wrong?